Trial Profile
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Prophylactic Cytomegalovirus Plasmid DNA Vaccine in Healthy Adults
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 27 May 2016
Price :
$35
*
At a glance
- Drugs VCL 6365 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions
- 18 May 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Nov 2015 New trial record